Strategies against methicillin-resistant Staphylococcus aureus persisters
Chronic Staphylococcus aureus infections are complicated by frequent relapses not only from the development of drug resistance to conventional antibiotics, but also through the formation of persister bacterial cells. Bacterial persisters are in a transient, metabolically inactive state, making conve...
Gespeichert in:
| Veröffentlicht in: | Future medicinal chemistry 2018-04, Vol.10 (7), p.779-794 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 794 |
|---|---|
| container_issue | 7 |
| container_start_page | 779 |
| container_title | Future medicinal chemistry |
| container_volume | 10 |
| creator | Kim, Wooseong Hendricks, Gabriel L Tori, Katerina Fuchs, Beth B Mylonakis, Eleftherios |
| description | Chronic Staphylococcus aureus infections are complicated by frequent relapses not only from the development of drug resistance to conventional antibiotics, but also through the formation of persister bacterial cells. Bacterial persisters are in a transient, metabolically inactive state, making conventional antibiotics that target essential cellular growth processes ineffective, resulting in high clinical failure rates of antibiotic chemotherapy. The development of new antibiotics against persistent S. aureus is an urgent issue. Over the last decade, new strategies to identify S. aureus persister-active compounds have been proposed. This review summarizes the proposed targets, antipersister compounds and innovative methods that may augment conventional antibiotics against S. aureus persisters. The reviewed antipersister strategies can be summarized as two broad categories; directly targeting growth-independent targets and potentiating existing, ineffective antibiotics by aiding uptake or accessibility. |
| doi_str_mv | 10.4155/fmc-2017-0199 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6077763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2018015375</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-284e1fcc40ef744fc044ec160f95a15d89d08f970d01968d54af23c74bc35013</originalsourceid><addsrcrecordid>eNpVkU1rAyEQhqW0NCHNsdeSYy-2uuqql0IJ_QgEekjuYlxNLPuRqlvIv69L0tB6mBHm8R1nXgBuMXqgmLFH1xhYIMwhwlJegDHmrIRCFvzyfMdyBKYxfqJ8SCFkya7BqJCslJIVY7BYpaCT3XobZ3qrfRvTrLFp542va9_CYKOPSbdptkp6vzvUnemM6TPcB5vT3oYByPEGXDldRzs95QlYv76s5-9w-fG2mD8voSGCJ1gIarEzhiLrOKXOIEqtwSVykmnMKiErJJzkqMozlaJiVLuCGE43hjCEyQQ8HWX3_aaxlbFtHqBW--AbHQ6q0179r7R-p7bdtyoR57wkWeD-JBC6r97GpBofja1r3dqujyrvUyDMCGcZhUfUhC7GYN25DUZqMEBlA4YHXA0GZP7u79_O9O-6yQ_FFoPB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2018015375</pqid></control><display><type>article</type><title>Strategies against methicillin-resistant Staphylococcus aureus persisters</title><source>MEDLINE</source><source>PubMed Central</source><creator>Kim, Wooseong ; Hendricks, Gabriel L ; Tori, Katerina ; Fuchs, Beth B ; Mylonakis, Eleftherios</creator><creatorcontrib>Kim, Wooseong ; Hendricks, Gabriel L ; Tori, Katerina ; Fuchs, Beth B ; Mylonakis, Eleftherios</creatorcontrib><description>Chronic Staphylococcus aureus infections are complicated by frequent relapses not only from the development of drug resistance to conventional antibiotics, but also through the formation of persister bacterial cells. Bacterial persisters are in a transient, metabolically inactive state, making conventional antibiotics that target essential cellular growth processes ineffective, resulting in high clinical failure rates of antibiotic chemotherapy. The development of new antibiotics against persistent S. aureus is an urgent issue. Over the last decade, new strategies to identify S. aureus persister-active compounds have been proposed. This review summarizes the proposed targets, antipersister compounds and innovative methods that may augment conventional antibiotics against S. aureus persisters. The reviewed antipersister strategies can be summarized as two broad categories; directly targeting growth-independent targets and potentiating existing, ineffective antibiotics by aiding uptake or accessibility.</description><identifier>ISSN: 1756-8919</identifier><identifier>EISSN: 1756-8927</identifier><identifier>DOI: 10.4155/fmc-2017-0199</identifier><identifier>PMID: 29569952</identifier><language>eng</language><publisher>England: Future Science Ltd</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Antineoplastic Agents - pharmacology ; Bacterial Proteins - metabolism ; Cell Membrane Permeability - drug effects ; Disease Models, Animal ; Drug Approval - legislation & jurisprudence ; Drug Discovery ; Drug Repositioning ; Humans ; Methicillin-Resistant Staphylococcus aureus - drug effects ; Microbial Sensitivity Tests ; Peptide Hydrolases - metabolism ; Review ; Staphylococcal Infections - drug therapy ; Staphylococcal Infections - microbiology ; United States ; United States Food and Drug Administration</subject><ispartof>Future medicinal chemistry, 2018-04, Vol.10 (7), p.779-794</ispartof><rights>2018 Newlands Press 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-284e1fcc40ef744fc044ec160f95a15d89d08f970d01968d54af23c74bc35013</citedby><cites>FETCH-LOGICAL-c387t-284e1fcc40ef744fc044ec160f95a15d89d08f970d01968d54af23c74bc35013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077763/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077763/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29569952$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Wooseong</creatorcontrib><creatorcontrib>Hendricks, Gabriel L</creatorcontrib><creatorcontrib>Tori, Katerina</creatorcontrib><creatorcontrib>Fuchs, Beth B</creatorcontrib><creatorcontrib>Mylonakis, Eleftherios</creatorcontrib><title>Strategies against methicillin-resistant Staphylococcus aureus persisters</title><title>Future medicinal chemistry</title><addtitle>Future Med Chem</addtitle><description>Chronic Staphylococcus aureus infections are complicated by frequent relapses not only from the development of drug resistance to conventional antibiotics, but also through the formation of persister bacterial cells. Bacterial persisters are in a transient, metabolically inactive state, making conventional antibiotics that target essential cellular growth processes ineffective, resulting in high clinical failure rates of antibiotic chemotherapy. The development of new antibiotics against persistent S. aureus is an urgent issue. Over the last decade, new strategies to identify S. aureus persister-active compounds have been proposed. This review summarizes the proposed targets, antipersister compounds and innovative methods that may augment conventional antibiotics against S. aureus persisters. The reviewed antipersister strategies can be summarized as two broad categories; directly targeting growth-independent targets and potentiating existing, ineffective antibiotics by aiding uptake or accessibility.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Bacterial Proteins - metabolism</subject><subject>Cell Membrane Permeability - drug effects</subject><subject>Disease Models, Animal</subject><subject>Drug Approval - legislation & jurisprudence</subject><subject>Drug Discovery</subject><subject>Drug Repositioning</subject><subject>Humans</subject><subject>Methicillin-Resistant Staphylococcus aureus - drug effects</subject><subject>Microbial Sensitivity Tests</subject><subject>Peptide Hydrolases - metabolism</subject><subject>Review</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcal Infections - microbiology</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1756-8919</issn><issn>1756-8927</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1rAyEQhqW0NCHNsdeSYy-2uuqql0IJ_QgEekjuYlxNLPuRqlvIv69L0tB6mBHm8R1nXgBuMXqgmLFH1xhYIMwhwlJegDHmrIRCFvzyfMdyBKYxfqJ8SCFkya7BqJCslJIVY7BYpaCT3XobZ3qrfRvTrLFp542va9_CYKOPSbdptkp6vzvUnemM6TPcB5vT3oYByPEGXDldRzs95QlYv76s5-9w-fG2mD8voSGCJ1gIarEzhiLrOKXOIEqtwSVykmnMKiErJJzkqMozlaJiVLuCGE43hjCEyQQ8HWX3_aaxlbFtHqBW--AbHQ6q0179r7R-p7bdtyoR57wkWeD-JBC6r97GpBofja1r3dqujyrvUyDMCGcZhUfUhC7GYN25DUZqMEBlA4YHXA0GZP7u79_O9O-6yQ_FFoPB</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Kim, Wooseong</creator><creator>Hendricks, Gabriel L</creator><creator>Tori, Katerina</creator><creator>Fuchs, Beth B</creator><creator>Mylonakis, Eleftherios</creator><general>Future Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180401</creationdate><title>Strategies against methicillin-resistant Staphylococcus aureus persisters</title><author>Kim, Wooseong ; Hendricks, Gabriel L ; Tori, Katerina ; Fuchs, Beth B ; Mylonakis, Eleftherios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-284e1fcc40ef744fc044ec160f95a15d89d08f970d01968d54af23c74bc35013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Bacterial Proteins - metabolism</topic><topic>Cell Membrane Permeability - drug effects</topic><topic>Disease Models, Animal</topic><topic>Drug Approval - legislation & jurisprudence</topic><topic>Drug Discovery</topic><topic>Drug Repositioning</topic><topic>Humans</topic><topic>Methicillin-Resistant Staphylococcus aureus - drug effects</topic><topic>Microbial Sensitivity Tests</topic><topic>Peptide Hydrolases - metabolism</topic><topic>Review</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcal Infections - microbiology</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Wooseong</creatorcontrib><creatorcontrib>Hendricks, Gabriel L</creatorcontrib><creatorcontrib>Tori, Katerina</creatorcontrib><creatorcontrib>Fuchs, Beth B</creatorcontrib><creatorcontrib>Mylonakis, Eleftherios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Future medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Wooseong</au><au>Hendricks, Gabriel L</au><au>Tori, Katerina</au><au>Fuchs, Beth B</au><au>Mylonakis, Eleftherios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strategies against methicillin-resistant Staphylococcus aureus persisters</atitle><jtitle>Future medicinal chemistry</jtitle><addtitle>Future Med Chem</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>10</volume><issue>7</issue><spage>779</spage><epage>794</epage><pages>779-794</pages><issn>1756-8919</issn><eissn>1756-8927</eissn><abstract>Chronic Staphylococcus aureus infections are complicated by frequent relapses not only from the development of drug resistance to conventional antibiotics, but also through the formation of persister bacterial cells. Bacterial persisters are in a transient, metabolically inactive state, making conventional antibiotics that target essential cellular growth processes ineffective, resulting in high clinical failure rates of antibiotic chemotherapy. The development of new antibiotics against persistent S. aureus is an urgent issue. Over the last decade, new strategies to identify S. aureus persister-active compounds have been proposed. This review summarizes the proposed targets, antipersister compounds and innovative methods that may augment conventional antibiotics against S. aureus persisters. The reviewed antipersister strategies can be summarized as two broad categories; directly targeting growth-independent targets and potentiating existing, ineffective antibiotics by aiding uptake or accessibility.</abstract><cop>England</cop><pub>Future Science Ltd</pub><pmid>29569952</pmid><doi>10.4155/fmc-2017-0199</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-8919 |
| ispartof | Future medicinal chemistry, 2018-04, Vol.10 (7), p.779-794 |
| issn | 1756-8919 1756-8927 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6077763 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Anti-Bacterial Agents - pharmacology Antineoplastic Agents - pharmacology Bacterial Proteins - metabolism Cell Membrane Permeability - drug effects Disease Models, Animal Drug Approval - legislation & jurisprudence Drug Discovery Drug Repositioning Humans Methicillin-Resistant Staphylococcus aureus - drug effects Microbial Sensitivity Tests Peptide Hydrolases - metabolism Review Staphylococcal Infections - drug therapy Staphylococcal Infections - microbiology United States United States Food and Drug Administration |
| title | Strategies against methicillin-resistant Staphylococcus aureus persisters |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A43%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strategies%20against%20methicillin-resistant%20Staphylococcus%20aureus%20persisters&rft.jtitle=Future%20medicinal%20chemistry&rft.au=Kim,%20Wooseong&rft.date=2018-04-01&rft.volume=10&rft.issue=7&rft.spage=779&rft.epage=794&rft.pages=779-794&rft.issn=1756-8919&rft.eissn=1756-8927&rft_id=info:doi/10.4155/fmc-2017-0199&rft_dat=%3Cproquest_pubme%3E2018015375%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2018015375&rft_id=info:pmid/29569952&rfr_iscdi=true |